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Aims and Method. The present study examined the relationship between the metabolic risk profile (MRP) and total testosterone
(TT) and free testosterone using the free androgen index (FAI) and sex hormone binding globulin (SHBG) in 36 Caucasian
American (CA) and 30 African-American (AA) women volunteering for a weight loss study. Results. After controlling for age,
significant relationships were found between TT and diastolic blood pressure (P = .004 and P = .015 in CA and AA women,
resp.). Additionally, total cholesterol (P = .003), low density lipoprotein cholesterol (P = .004), apolipoprotein B (P = .006), and
the total cholesterol/high density lipoprotein cholesterol (P = .027) were significantly related to TT in AA women only. In CA
women, similar measures of glucose/insulin status related to FAI, were also related to SHBG. In both CA and AA women, SHBG
was related to waist (P = .031 and P = .022 resp.). Conclusion. Our findings showed racial disparities in the relationship between
the sex steroid milieu and the MRP in overweight/obese CA and AA women.

1. Introduction
In women, a more android fat distribution pattern signified
by increased visceral adipose tissue (VAT) is associated with
high testosterone and low-sex hormone binding globulin
(SHBG), adverse lipids and lipoproteins, and altered glucose/insulin homeostasis [1, 2]. Since sex steroids and SHBG
serve as a marker of androgen status, they may be considered
a valuable marker of metabolic variables associated with
cardiovascular disease (CVD) risk [3].
In a large study of both pre- and postmenopausal
women, Bell and colleagues [4] confirmed the importance
of SHBG as an independent predictor of the metabolic
risk profile (MRP) in women across the lifespan. However,
despite higher rates of CVD [5], obesity [6], and type II
diabetes [7], few studies have targeted overweight or obese
African-American (AA) women.
In premenopausal women in the SWAN study [8],
investigators did compare racial groups and found a sig-

nificant correlation between SHBG, testosterone, and the
MRP in minority women. Their results showed consistent
hormone-risk factor relationships across racial groups that
in some instances appeared stronger in Asian and Caucasian
women. They also showed significant diﬀerences between
testosterone and triglycerides (TG) in Black and Hispanic
women. However, due to large BMI variances found among
racial groups, investigators cautioned against comparing
relationships across racial lines. In contrast, Berman and
colleagues [9] found several significant relationships between
SHBG and the MRP in postmenopausal Caucasian American
(CA) women despite the fact that no significant relationships
were evidenced in postmenopausal AA women. Unfortunately, investigators failed to control for intra-abdominal or
VAT in either study, leaving potential mediating processes
uninvestigated across racial groups.
In a study of premenopausal Hispanic and CA women
by Haﬀner and colleagues [10, 11] a significant inverse relationship between SHBG, insulin resistance, and atherogenic
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lipids was found to be similar across Hispanic and
CA women supporting similarity in these relationships
across racial lines. The similar and significant relationships
observed in this study remained after controlling for BMI
and VAT [10]. However, controlling for insulin negated a
number of relationships that were previously significant,
demonstrating the importance of insulin in modulating this
relationship. In contrast, other investigations found that after
controlling for VAT, neither SHBG nor testosterone were
related to the MRP reaﬃrming the importance of VAT in
modulating this relationship [1, 2].
Given the inconsistencies in the literature and lack of
emphasis in overweight/obese women, the present study
examined total testosterone (TT), free testosterone, using the
free androgen index (FAI) and SHBG, in relation to MRP
in a group of overweight/obese premenopausal CA and AA
women. A secondary purpose was to examine whether these
relationships were mediated by VAT or insulin in each group
of women.

2. Subjects and Methods
2.1. Subjects. Participants were volunteers interested in a
weight loss program. Subjects were required to be premenopausal, weight stable for a minimum of three months,
possessing a BMI above 25, and free of known metabolic disease such as diabetes, hyperlipidemia, hypertension, polycystic ovary syndrome, or CVD. Subjects who were pregnant or
lactating, amenorrheic, or taking medications or hormones
that would aﬀect blood pressure (BP), carbohydrate, or
lipid metabolism were excluded from the study. All subjects
were required to be eumenorrheic having a normal monthly
menstrual cycle for the proceeding six months. A total of
66 subjects (36 CA; 30 AA) met the criteria necessary for
participation in the study. One weekday and one weekend
day were randomly selected for testing and evaluation of
participants. A second consecutive weekday and weekend day
were also provided to maximize participation of all subjects.
Subjects gave informed consent and completed all testing
procedures in accordance with the ethical standards and
guidelines of the Institutional Review Board guidelines for
human subjects at the University of Miami.
2.2. Physical and Anthropometric Measurements. Body
weight was measured to the nearest 0.1 kg. Height was
measured to the nearest 0.5 cm, and BMI was calculated
as weight (kg) divided by the square of height (m2 ).
Waist circumference was measured using a spring tension
measuring tape (Gays Mills, WI) midway between the
lower rib margin and iliac crest, [12]. All anthropometric
measurements were performed by the same investigator who
recorded the mean of the two measurements to the nearest
1.0 mm.
Following an overnight fast, systolic and diastolic blood
pressure (SBP and DBP, resp.) were taken in one setting
following a 5-min rest interval. Duplicate blood pressure
measurements were taken from the left upper arm, averaged,
and recorded to the nearest 2.0 mmHg.
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2.3. Magnetic Resonance Imaging (MRI). The abdominal
region was measured by MRI using a 1.5T instrument
(Siemens Medical Systems, Iselin, NJ). Spin-echo imaging
was performed using a T1-weighted sequence with a 147ms repetition time and 4.8 ms echo time. Ten mm thick
images with a 2.5-mm gap between images were obtained
during a single breath hold sequence. A total of seven images
were obtained in each subject with the central slice obtained
at the L4-L5 intervertebral disk space. VAT was defined
as adipose tissue contained within the boundaries of the
rectus abdominis, internal obliques, quadratus lumborum,
and long back muscles while subcutaneous adipose tissue
(SAT) was adipose tissue located between the skin and the
same group of muscles. Both VAT and SAT were computed by
summing the respective VAT and SAT partial volumes (cm3 )
and converting to liters.
2.4. Serum Measurements. Blood was withdrawn from the
antecubital vein after a 12-h fast and following centrifugation. Serum was analyzed within one week of withdrawal. All
serum measurements were taken while subjects were seated
quietly for at least five minutes. Total cholesterol [13], highdensity lipoprotein cholesterol (HDL) [14], its subfractions
[15], and TG [16] were measured by the Diabetes Research
Institute Lipid Laboratory, University of Miami. Serum standards used for calibration were developed by the Diabetes
Research Institute and calibrated against serum samples from
the Centers for Disease Control and Prevention Laboratory,
Atlanta, GA. Very low density lipoprotein cholesterol was
estimated by TG divided by five, and low density lipoprotein
cholesterol (LDL) was indirectly calculated by subtracting
HDL and very low density lipoprotein cholesterol from total
cholesterol [17].
The peak particle diameter for major LDL subfractions
was determined on a gel scan based upon standards of known
diameter as described by Krauss and Burke [18]. The LDL
size of the predominant peak for a subject was identified as
the subjects’ LDL peak particle size (pps).
Apolipoprotein B in serum was measured by turbidimetric immunoassay using a commercially available kit (Incstar,
Stillwater, MN) according to procedures outlined by the
manufacturers. All apolipoprotein B procedures have been
developed in accordance with the guidelines set forth by the
International Federation of clinical chemistry.
Fasting glucose levels were determined spectrophotometrically at a wavelength of 340 nm using a hexokinase reaction
developed by Roche (Roche Diagnostic System, Nutley, NJ).
Serum insulin was measured by radioimmunoassay of serum
using a Coat-A-Count insulin procedure (Diagnostic Products, Los Angeles, CA). The insulin resistance was assessed
by using the homeostasis model assessment (HOMA) index,
which divides the product of fasting insulin (µU/mL) and
glucose (mmol/L) by 22.5 [19].
Serum SHBG was analyzed by immunoradiometric assay
(Siemens Health Care Diagnostics; Los Angeles, CA). The TT
was analyzed by Coat-A-Count radioimmunoassay using a
testosterone-specific antibody (Siemens Health Care Diagnostics; Los Angeles, CA). Quality control procedures for
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accuracy and reliability in the laboratory yielded intra-assay
and interassay coeﬃcients of variation of less than 5% for
SHBG and less than 7.5% for TT. The FAI was the ratio of
TT/SHBG in the same unit [20, 21].
2.5. Additional Assessments. Nutrient intake and alcohol
consumption (g/day) were recorded using a three-day food
log and analyzed using the Dine System (Buﬀalo, N.Y. 1994).
Cigarettes smoked were determined using a medical history questionnaire. Subjects were administered the College
Alumnus Questionnaire developed by Paﬀenbarger et al. [22]
for evaluating daily physical activity. Education experience
was measured using a 1–5 categorical scale modified from
Rosmond et al. [23]. All subjects completed the Daily Stress
Inventory which has been shown to be a significant correlate
of endocrine measures of stress [24].
2.6. Statistical Analysis. All statistical analyses were completed using the Statistical Package for the Social Sciences, version 10.1 [25]. Means ± standard deviations of
all variables were calculated for participants. Natural log
transformation was used for TG, SHBG, and FAI while
the square root of TT was used to achieve normality of
distribution. Student’s t-tests for unpaired samples were
used to assess diﬀerences between racial groups. Since age
showed a trend toward significant diﬀerences in CA and AA
women, Pearson’s correlation coeﬃcients were performed
after controlling for age, to examine the relationship between
SHBG and sex steroids with the MRP in CA and AA women.
These correlations were also conducted after controlling for
VAT and insulin.

3. Results
3.1. Descriptives. A total of 66 subjects, 36 CA and 30 AA
women, were evaluated for subject characteristics. A comparison between groups indicated that CA women had
significantly higher VAT and TG levels than AA women
(P < .05 for both). There was also a trend toward significant
diﬀerences in waist circumference (P = .058), age (P = .063),
and SHBG (P = .073). No other significant diﬀerences or
trends in metabolic variables were noted between groups.
3.2. Association between Total Testosterone and the Metabolic
Risk Profile. Pearson’s correlation coeﬃcient showed a significant inverse correlation between TT and BP (P = .014
and P = .004 for SBP and DBP, resp.) indicating that higher
TT was associated with lower BP in CA women. This was
observed concomitant with a positive relationship between
SAT and TT (P = .006). In AA women, significant inverse
relationships were also observed between TT and DBP (P =
.015) as well as total cholesterol (P = .003), LDL (P = .004),
Apo B (P = .006), and total cholesterol/HDL (P = .027).
In both CA and AA women, all significant relationships
remained, after controlling for VAT or insulin.
3.3. Association between Free Androgen Index and the
Metabolic Risk Profile. Pearson correlation coeﬃcient
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showed significant positive relationships between FAI and
waist circumference (P = .048), SAT (P = .026), glucose,
insulin, and HOMA IR (P ≤ .01 for all) and a negative
relationship with HDL (P = .043) in CA women. Similar to
what was observed for TT, significant relationships between
FAI and DBP (P = .018), total cholesterol (P = .009),
LDL (P = .010), and Apo B (P = .029) were found for
AA women. Controlling for VAT had no impact upon
aforementioned relationships in either CA or AA women.
Controlling for insulin, however, negated all significant
relationships between FAI and HOMA IR as well as serum
lipid and lipoproteins in both CA and AA women.
3.4. Association between Sex Hormone Binding Globulin
and the Metabolic Risk Profile. In CA women, SHBG was
significantly and positively related to waist circumference
(P = .031), VAT (P = .004), glucose (P = .009), insulin
(P = .001), and HOMA IR (P = .001). In AA women, the
only significant associations were observed between SHBG
and waist circumference (P = .022). However, there was a
trend toward significant relationships between SHBG and
VAT (P = .096), insulin (P = .056), HOMA IR (P =
.090), and HDL (P = .094) in AA women. Adjusting
for insulin negated all significant correlations in both CA
and AA women. Adjusting for VAT negated the significant
relationship between SHBG and waist circumference in AA
women.

4. Discussion
The present study revealed several interesting findings relevant to sex steroids, SHBG, and the MRP in CA and AA
women. As expected, CA women showed higher VAT and
TG levels than AA women, which had been reported in
previous studies [26, 27]. After controlling for VAT, however,
there were no longer significant diﬀerences in TG levels
between groups indicating that lower TG in AA women were
accounted for, in part, by their lower VAT levels. Controlling
for VAT also eliminated any trends toward significance by
group for waist circumference and SHBG, highlighting the
importance of VAT in these relationships. In contrast, other
studies have shown FAI to be significantly lower [8] and
SHBG significantly higher [28] in Black compared to White
subjects.
Interestingly, our findings showed an inverse relationship
between TT and several metabolic variables observed in both
CA and AA women (Table 2). The majority of research has
suggested that women possessing higher androgens tend to
display a more adverse MRP. Other studies, however, have
shown no association between TT and the MRP [1, 2]. Still
others have reported favorable associations between TT and
metabolic variables [29, 30]. Equivocal results may be found
because TT represents a combination of the more bioactive,
free form as well as the inactive form bound with other
proteins, that is, SHBG, albumin. In the present study, as TT
went up, BP went down and this relationship was observed
in both CA and AA women.
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Table 1: Comparison of subject characteristics between CA and AA women using student’s t-tests for unpaired samples.

Characteristics
Age (y)
Height (m)
Weight (kg)
BMI (kg/m2 )
Resting heart rate (beats/min)
Stressb
Educationc
Physical activity (kcal/wk)
Cigarettes (no./d)
Alcohol
Metabolic risk profile
Waist (cm)
WHR
SAT (L)
VAT (L)
Glucose (mmol/L)d
Insulin (µU/mL)
HOMA IR
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Triglycerides (mg/dL)
Total cholesterol (mmol/L)
HDL (mmol/L)
HDL2 (mmol/L)
LDL (mmol/L)
LDL pps (nmol/L)
Apo B (mg/dL)
Total cholesterol/HDL
Lp(a) (mg/dL)
SHBG and Sex Steroids
SHBG (nmol/L)e
TT (ng/mL)e
FAI

CA women (n = 36)
41.94 ± 7.10
1.64 ± 0.07
94.79 ± 15.72
35.12 ± 5.35
73.67 ± 11.04
67.71 ± 21.37
2.56 ± 0.50
983.65 ± 1, 033.60
2.11 ± 6.96
5.56 ± 13.78

AA women (n = 30)
37.97 ± 9.94
1.62 ± 0.06
91.84 ± 14.03
34.88 ± 4.4
76.57 ± 10.90
69.28 ± 31.64
2.30 ± 0.66
892.88 ± 895.74
1.53 ± 5.10
2.27 ± 5.65

Pa
.063
.168
.427
.850
.289
.815
.077
.723
.707
.226

107.29 ± 14.50
0.86 ± 0.06
4.68 ± 1.28
1.20 ± 0.48
4.80 ± 0.57
14.84 ± 8.13
3.13 ± 1.81
126.67 ± 14.89
82.11 ± 10.13
144.50 ± 78.44
5.34 ± 1.32
1.44 ± 0.42
0.36 ± 0.23
3.10 ± 0.96
27.11 ± 0.71
106.50 ± 29.22
3.91 ± 1.26
24.86 ± 20.60

101.03 ± 11.27
0.87 ± 0.08
4.51 ± 1.40
0.76 ± 0.30
4.76 ± 5.77
14.75 ± 5.77
3.20 ± 1.39
123.00 ± 14.21
82.20 ± 8.70
107.77 ± 67.58
5.14 ± 1.41
1.45 ± 0.29
0.41 ± 0.28
3.13 ± 1.25
27.15 ± 0.57
102.70 ± 30.69
3.69 ± 1.35
36.85 ± 23.59

.058
.536
.603
< .001
.758
.957
.878
.313
.970
.048
.552
.931
.428e
.909
.799
.609
.488
.093

33.88 ± 22.98
0.27 ± 0.11
4.24 ± 3.55

43.80 ± 30.73
0.33 ± 0.19
4.11 ± 4.83

.073e
.170e
.685e

Values are means ± SD. SAT indicates volume of subcutaneous adipose tissue; VAT indicates volume of visceral adipose tissue; IR, insulin resistance calculated
as (insulin, µU/mL × glucose, mmol/L) ÷ 22.5; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; LDL pps-low-density
lipoprotein, peak particle size; Apo B, apolipoprotein B; SHBG, sex hormone binding globulin; TT, total testosterone, FAI, free androgen index, calculated as
TT (ng/mL) × 3.467 × 100/SHBG (nmol/L).
a Values obtained from a Student’s t-test for unpaired samples.
b Graded numerically, with the higher number indicating a higher stress level.
c Graded on a scale of 1 to 5, with the higher number indicating a higher level of education.
d One outlier was excluded from the analysis.
e t-test performed on transformed values.

Paradoxically TT has been reported to have both
vasodilatory and vasoconstrictive eﬀects [31]. According to
Livingstone and Collison [32], there may be a “physiological window” within which normal androgen/estrogen
levels confer health benefits and beyond which may show
detrimental eﬀects. Based upon the literature, our women
demonstrated low normal levels of TT. If estrogen levels fell
along the same lines, a more balanced androgen/estrogen
ratio would have translated into a more favorable association
between TT and the MRP.

Unexpected was the significant inverse relationship
between TT and several lipoproteins in AA women. Total
cholesterol/HDL is considered one of the most powerful
predictors of CVD [33] and in AA women, Apo B, another
marker of atherogenic risk, shared almost 28% of its variance
with TT. Thus, at a given level of TT, AA women demonstrated lower levels of total cholesterol, LDL, and ApoB than
CA women. This contrasts with other studies using minority
groups [8, 34] which showed very little if any association
between TT and the MRP. In the Swan study [8], TT was
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Table 2: Pearson’s correlation coeﬃcients between total testosterone (square root) and the metabolic risk profile after adjusting for age.
Metabolic risk profile
BMI (kg/m2 )

Caucasian American
women (r value)

P value

African American
women (r value)

P value

0.124

.478

−0.072

.711

WAIST (cm)

0.235

.174

−0.117

.547

SAT (L)

0.452

.006

−0.104

.593

VAT (L)

0.100

.567

0.176

.361

Glucose (mmol/L)

0.220

.211

−0.02

.924

Insulin (uµ/mL)

0.281

.108

0.004

.986

HOMA IR

0.246

.161

0.008

.967

SBP (mmHg)

−0.411

.014

−0.298

.116

DBP (mmHg)

−0.481

.004

−0.448

.015

0.015

.934

−0.175

.394

−0.259

.140

−0.555

.003

HDL (mmol/L)

−0.242

.168

−0.058

.778

HDL2 (mmol/L)

−0.025

.888

−0.267

.187
.004

TG (mg/dL)
Total cholesterol
(mmol/L)

LDL (mmol/L)

−0.320

.065

−0.550

LDL pps (nmol/L)

−0.029

.871

0.238

.241

Apo B (mg/dL)
Total
cholesterol/HDL-C

−0.239

.173

−0.528

.006

−0.101

.571

−0.433

.027

Lp (a)

−0.082

.654

−0.008

.967

SBP, systolic blood pressure, DBP, diastolic blood pressure, SAT, subcutaneous adipose tissue volume, VAT, visceral adipose tissue volume, HOMA IR, insulin
resistance calculated as (insulin × glucose) ÷ 22.5, HDL, high density lipoprotein cholesterol, HDL2 , high-density lipoprotein subfraction 2, LDL, low-density
lipoprotein cholesterol, Apo B, apolipoprotein B, LDL pps, low density lipoprotein peak particle size, TG, triglycerides, log transformed, BMI, body mass
index, WAIST, waist circumference.

correlated with TG accounting for only a modest diﬀerence
by race in this variable. Interestingly, the incidence of the
Metabolic Syndrome [35] and of coronary heart disease [36]
is only slightly greater in AA than CA women despite AA
women having much greater rates of overweight/obesity.
This, however, may be more closely related to diﬀerences in
other risk factors such as high blood pressure and diabetes
which tend to be higher in AA women.
Tchernof and Després [3] have maintained that VAT
plays an important role in moderating the relationship
between sex steroids and coronary risk factors. However,
when we controlled for VAT, all significant correlations with
TT remained. They also remained when we controlled for
insulin. Thus, the mechanisms responsible for the significant
relationship found in AA women require further study.
Past research shows no consensus opinion regarding the
relationship between endogenous steroids and serum lipids
or lipoproteins [3]. Our finding of a significant relationship
in AA women adds to the controversy surrounding this issue.
As expected, significant and positive relationships were
observed between FAI and insulin/glucose status, as well as
central obesity measures (SAT and waist) [1, 2, 10, 11]. In
AA women, a diﬀerent case scenario was observed. Similar to
that shown with TT, FAI was significantly related to DBP and
atherogenic lipoproteins (total cholesterol, LDL, and Apo B)
but not measures of glucose/insulin status.

Upon further evaluation, CA compared to AA women
showed roughly double the magnitude of correlation
between FAI and either fasting insulin or HOMA IR.
Furthermore, glucose shared almost 20% of its variance with
FAI in CA women, while in AA women, there was virtually no
shared variance between glucose and FAI. This discrepancy
accounted for an FAI/glucose relationship ten times greater
in CA than AA women.
Other studies [37, 38] have suggested that AA women
are more insulin resistant than CA women even after
adjustment for VAT [37]. In postmenopausal women, Ryan
and colleagues [37] have shown a 60% lower glucose uptake
concomitant with a higher insulin level in AA compared to
CA women. Although there were no significant diﬀerences
between fasting insulin or HOMA IR in CA and AA women,
our data reaﬃrms racial diﬀerences in the relationship
between FAI and the MRP specifically with regard to the
FAI/glucose relationship. This is particularly relevant since
diabetes risk is 2.4 times greater in AA than CA women [7].
Further research is warranted to support the mechanisms
responsible for these diﬀerences.
Our work contrasted with the findings of Pedersen et al.
[2] who did not find significant relationships between FAI
and the MRP, independent of VAT. The only exception
was the relationship between HDL and FAI. In fact, our
results showed that insulin played a more critical role than
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Table 3: Pearson correlation coeﬃcients between free androgen index (log transformed) and the metabolic risk profile after adjusting for
age.
Metabolic risk profile
BMI (kg/m2 )
WAIST (cm)
SAT (L)
VAT (L)
Glucose (mmol/L)
Insulin (uµ/mL)
HOMA IR (ratio)
SBP (mmHg)
DBP (mmHg)
TG (mg/dL)
Total cholesterol
(mmol/L)
HDL (mmol/L)
HDL2 (mmol/L)
LDL (mmol/L)
LDL pps (nmol/L)
Apo B (mg/dL)
Total
cholesterol/HDL-C
Lp (a)

Caucasian American
women (r value)
0.188
0.337
0.376
0.308
0.519
0.436
0.478
−0.197
−0.211
0.195

P value

P value

.279
.048
.026
.072
.002
.0100
.004
.257
.223
.269

African American
women (r value)
0.149
0.323
−0.080
0.316
−0.044
0.264
0.236
−0.301
−0.435
−0.067

−0.196

.269

−0.504

.009

−0.349

−0.249
−0.499

−0.151

.043
.231
.149
.598
.192

−0.428

.220
.243
.010
.891
.029

0.035

.844

−0.297

.141

−0.097

.594

−0.125

.542

−0.211
−0.253
−0.092

−0.238
−0.028

.440
.087
.682
.095
.829
.192
.247
.112
.018
.746

BMI, body mass index, WAIST, waist circumference, SAT, subcutaneous adipose tissue volume, VAT, visceral adipose tissue volume, SBP systolic blood
pressure, DBP, diastolic blood pressure, HOMA IR, insulin resistance calculated as (insulin × glucose) ÷ 22.5; HDL, high-density lipoprotein cholesterol,
HDL2 , high density lipoprotein subfraction 2, LDL, low density lipoprotein cholesterol, LDL pps, low-density lipoprotein peak particle size, Apo B,
apolipoprotein B, TG, triglycerides, log transformed.

VAT in modulating these relationships. Upon controlling for
insulin, the relationship between FAI and all lipid variables
in both CA and AA women was negated. These findings are
supported by Haﬀner and colleagues [11, 39] who proposed
that insulin plays a more primary role in relation to the
sex steroid milieu. Insulin is reported to stimulate androgen
production in the ovary, and bioavailable androgens may be
more closely associated with insulin and insulin resistance
[11, 40]. Androgens also play a role in modulating hepatic
lipase activity [2] which would explain subsequent changes
in the relationship between FAI and HDL, as well as TG
after controlling for insulin. It does not explain how insulin
modulates the relationship between FAI and other lipids such
as total cholesterol, LDL, or APO B, shown in AA women.
In CA women, the same four variables related to FAI were
also related to SHBG (waist, glucose, insulin, and HOMA
IR). Relationships were additionally observed between SHBG
and VAT. These relationships confirm the deleterious eﬀects
of low SHBG/high FAI reported in many previous studies [2,
4, 8, 10]. Furthermore, insulin has been shown to suppress
hepatocellular SHBG production [41] and both insulin and
VAT have been reported to impact the relationship between
SHBG and the MRP [1, 2, 10]. Controlling for insulin, but
not VAT, negated all significant relationships between SHBG
and the MRP in CA women. This indicates the importance
of insulin in modulating relationships between SHBG and
variables associated with CVD risk.

In AA women, the only significant relationship observed
with SHBG was waist circumference. At first glance our
findings mirror the results of those by Berman et al. [9]
who found significant relationships between SHBG and the
MRP in overweight/obese postmenopausal CA but not AA
women. They surmised that diﬀerences were related to a
higher postheparin lipase activity and a lower level of hepatic
lipase in AA women which would explain a greater capacity
to clear TG’s from circulation in their AA women. Our study
showed a lower VAT which was related to lower TG in AA
women. Thus, the mechanism proposed for racial diﬀerences
in their postmenstrual women may not be applicable to
premenopausal women in our study.
Upon further examination, however, there was a trend
toward significance between SHBG and insulin as well as
HOMA IR, HDL, and VAT in AA women (see Table 4).
Although these correlations were somewhat lower in AA
than CA women, they do not negate the fact that some
clinical associations may be occurring in AA women. In the
SWAN study [8] and the study by Sherif and colleagues
[34], they did find significant relationships between SHBG
and HDL in AA women, which were both lower than that
of AA women in the present study. This is likely due to
the much larger number of subjects in the SWAN study
and slightly higher number of AA subjects in the study by
Sherif [34]. Subjects in the SWAN study [8] also showed
considerably lower BMI levels than our study. Certainly, a
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Table 4: Pearson correlation coeﬃcients between sex hormone binding globulin (log transformed) and the metabolic risk profile after
adjusting for age.
Metabolic risk profile
BMI (kg/m2 )
WAIST (cm)
SAT (L)
VAT (L)
Glucose (mmol/L)
Insulin (uµ/mL)
HOMA IR (ratio)
SBP (mmHg)
DBP (mmHg)
TG (mg/dL)
Total cholesterol
(mmol/L)
HDL (mmol/L)
HDL2 (mmol/L)
LDL (mmol/L)
LDL pps (nmol/L)
Apo B (mg/dL)
Total cholesterol/HDL
Lp (a)

Caucasian American
women (r value)
−0.267
−0.365
−0.230
−0.478
−0.442
−0.527
−0.542
−0.191
−0.183
−0.331

P value

P value

.121
.031
.184
.004
.009
.001
.001
.271
.800
.056

African American
women (r value)
−0.171
−0.424
0.045
−0.315
−0.029
−0.379
−0.339
0.183
0.257
−0.137

−0.040

.820

−0.192

.373

0.262
0.300
0.117
0.164
−0.013
−0.111
0.071

.135
.085
.511
.355
.943
.533
.696

0.335
0.100
0.182
−0.233
−0.079
−0.021
−0.202

.094
.627
.373
.252
.700
.917
.322

.375
.022
.817
.096
.89
.056
.090
.341
.179
.504

BMI, body mass index, WAIST, waist circumference, SAT, subcutaneous adipose tissue volume, VAT, visceral adipose tissue volume, SBP systolic blood
pressure, DBP, diastolic blood pressure, HOMA IR, insulin resistance calculated as (insulin × glucose) ÷ 22.5; HDL, high-density lipoprotein cholesterol,
HDL2 , high-density lipoprotein subfraction 2, LDL, low-density lipoprotein cholesterol, LDL pps, low-density lipoprotein peak particle size, Apo B,
apolipoprotein B, TG, triglycerides, log transformed.

higher number of AA women in our study would have been
helpful.
It remains unclear as to why some of the aforementioned
relationships, particularly with regard to glucose/insulin
status, were considerably stronger in CA than AA women.
Investigators in the SWAN study [8] concluded that relationships were, in general, similar across racial lines being
stronger in certain racial groups and weaker in others. With
regard to the relationship between SHBG and the MRP, our
results tended to reinforce their findings.
There were, however, several limitations noted with
respect to this study. First, all relationships were based upon
a single blood draw at one time point. It would have been
better to obtain multiple samples particularly in a crosssectional study. Furthermore, an n of 66 subjects which
included a biracial group of women, limited our power.
Since this was a cross sectional study, it was diﬃcult to
determine any temporal or causal relationships between sex
steroids, SHBG, and the MRP. We could only speculate
primary relationships based upon the strength of the correlation analysis before and after controlling for potential
confounders, that is, VAT and insulin. Since many variables
were correlated with each other, it was diﬃcult to determine
if some relationships were operating independently or via
their association with other metabolic variables. Although
women were recruited from the same medical institution
and consisted of nurses, nurse assistants, and technicians,

it would have been helpful to examine the socioeconomic
status of CA and AA women. A few women in both
groups were in their mid to late 40’s and may have been
perimenopausal. This transition period prior to menopause
may be linked to a progressive reduction in ovarian function,
reduced estrogen levels, and stable androgen levels. Estrogen
measurements would have been helpful. Although age was
controlled for in all analysis, this may have aﬀected the
androgen/estrogen balance in several women. Furthermore,
blood sampling was done randomly and not at uniform
times in the menstrual cycle. Since total and LDL cholesterol
show variability across follicular and luteal phases of the
cycle [41], it may have aﬀected relationships or lack thereof
between the sex steroid milieu and serum lipoproteins in
CA and AA women. It would have been preferable to
sample all women at the same time in their menstrual
cycle; however, it is hoped that the random selection of
testing dates and blood withdrawal will have prevented any
undue influences in our results. Finally, free testosterone
was not measured directly but computed indirectly as FAI
using both TT and SHBG in the formulation. Although
FAI is considered a viable correlate of free testosterone, the
direct measurement of free testosterone would have been
preferable, particularly in women, in the low normal range.
Although investigators sampled first thing in the morning
following an overnight fast to reduce variability in androgen
levels, it is always preferable to measure free testosterone
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directly. Fortunately other confounding variables such as
physical activity, smoking, alcohol, and stress known to aﬀect
the MRP were not found to be significantly diﬀerent between
groups.

5. Conclusions
Given aforementioned limitations, several important findings were noted. First, independent of VAT or insulin, TT
showed several significant and cardioprotective relationships
with several variables in the MRP, in both CA and AA
women. Second, our study reinforced racial diﬀerences in
the relationship between androgens and the MRP. This was
evidenced by the significant relationships found between TT
and FAI and serum lipoproteins in AA women that were
absent in CA women. There were also significant relationships found between FAI and glucose/insulin status in CA
women that were absent in AA women. Furthermore, the
aforementioned relationships were not mediated by VAT but
were more strongly influenced by insulin. Racial diﬀerences
were also noted with respect to the strength of the relationship observed between SHBG and the MRP. These tended to
be stronger in CA women. Future research is recommended
to further elucidate the mechanisms responsible for these
contrasting relationships and trends in premenopausal CA
and AA women.
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